Abstract:Background Multidrug resistance (MDR) is one of the major problems in the treatment of cancer. Overcoming it is therefore expected to improve clinical outcomes for cancer patients. MDR is usually characterized by overexpression of ABC (ATP-binding cassette) protein transporters such as P-gp, MRP1, and ABCG2. Though the importance of ABC transporters for cancer cells is recognized, few studies have looked at its implications for the endothelial cells that are essential to tumor angiogenesis. This study investigated the expression and functions of these ABC transporters in endothelial cells in vitro and their potential contribution to cancer growth in mice. Methods Human micro vessel endothelial cells (HMEC-1) and human umbilical vein endothelial cells (HUVEC) were exposed to increasing doses of Doxorubicin (Dox) to induce ABC gene expression. Cell viability was then quantified by 3 H-thymidine and MTS assay. Flow cytometry, qPCR, and western blot were used to detect mRNA and the protein expression of P-gp, MRP1, and ABCG2. The intracellular accumulation of Rhodamine 123 (Rho) was used to evaluate drug efflux function and the inhibitors for P-gp, ABCG2, and MRP1 were used to verify their respective roles in vitro . In an attempt to evaluate drug resistance in endothelial cells in vivo , athymic mice were treated with Dox for 15 days before a MDA-MB-435 tumor graft to observe subsequent changes in the inhibition curves of tumor growth in response to Dox treatment. Furthermore, endothelial cells from multiple sites in these mice were also isolated to estimate their P-gp expression by flow cytometry. Results Drug resistance in HMEC-1 and HUVEC was successfully induced by the addition of Dox to the culture media. Two stabilized subcell lines of HMEC1 (HMECd1 and HMECd2) showed 15- and 24-fold increases in resistance. Tests also showed that these induced endothelial cells were cross-resistant to the structurally unrelated drugs Daunorubicin, Vinblastine, and Etoposide. P-gp protein levels increased four and six fold in HMECd1 and HMECd2 as revealed by western blot. The qPCR demonstrated 3.4- and 7.2-fold increases in P-gp, and a slight increase in ABCG2, gene expression. The Rho accumulation within these cells was inversely correlated with the expression levels of P-gp. The inhibitors of P-gp, but not of ABCG2 or MRP1, were able to block the induced endothelial cell resistance to Dox. Furthermore, we also showed that injecting Dox into healthy mice induced an increase in P-gp expression in endothelial cells. Using these pretreated mice in a tumor growth experiment, we observed a dramatic diminution in the therapeutic efficiency of Dox treatment, suggesting implications for drug resistance in mice endothelial cells supporting tumor growth. Conclusions ABC transporter expression can be induced in endothelial cells in vitro . This study also indicates that P-gp plays an important role in the acquisition of resistance to Dox in endothelial cells and that this reduces the efficiency of chemotherapy.

Multiple Drug Resistance Phenotype of Human Endothelial Cells Induced by Vascular Endothelial Growth Factor 165

Abstract 365: Autocrine Vascular Endothelial Growth Factor Signaling Mediates Survival and Chemoresistance of Human Colorectal Cancer Cells

[Autocrine Effect of Vascular Endothelial Growth Factor on the Proliferation of HaCaT Cells].

Abstract 1281: Endothelial Cells Promote the Cancer Stem Cell Phenotype of Human Colorectal Cancer Cells

Tumor Resistance to Anti-Vegf Therapy Through Up-Regulation of Vegf-C Expression

Induction of Acquired Drug Resistance in Endothelial Cells and Its Involvement in Anticancer Therapy

Overexpression Of Vascular Endothelial Growth Factor 165 (Vegf(165)) Protects Cardiomyocytes Against Doxorubicin-Induced Apoptosis

Anti-Vegf Treatment Interacts With Hypoxia-Driven Vascular Endothelial Growth Factor Loop Sensitivates Hepatoma Carcinoma Cells To Etoposide

Tumor Endothelial Expression of P-glycoprotein Upon Microvesicular Transfer of TrpC5 Derived from Adriamycin-Resistant Breast Cancer Cells.

Resistance of Smmc-7721 Hepatoma Cells to Etoposide in Hypoxia is Reversed by Vegf Inhibitor

Adaptive resistance of tumor cells to anti-vascular endothelial growth factor therapy: A reversible phenomenon

Vitamin E reverses multidrug resistance in vitro and in vivo

Hypoxia Induces Multidrug Resistance via Enhancement of Epidermal Growth Factor-Like Domain 7 Expression in Non-Small Lung Cancer Cells.

Variable Sensitivity of Endothelial Cells to Epirubicin in Xenografts of Human Nasopharyngeal Carcinoma CNE-2 Cells

Vascular Endothelial Growth Factor Enhances Cancer Cell Adhesion to Microvascular Endothelium in Vivo

P3-04-02: Bevacizumab Treatment Alters Intrinsic Subtypes in a VEGF-Reinforced Xenograft Model of ER-Positive Breast Cancer.

Inhibitory Effect of Antisense Vascular Endothelial Growth Factor 165 Eukaryotic Expression Vector on Proliferation of Hepatocellular Carcinoma Cells

Cross-drug Resistance to Sunitinib Induced by Doxorubicin in Endothelial Cells.

Vitamin E Succinate Overcomes Apoptosis Resistance in Multidrug-resistant K562/ADM Cells by Down-regulating Expression of mdr1 Gene and Its Product P-glycoprotein

Endothelial expression of autocrine VEGF upon the uptake of tumor-derived microvesicles containing oncogenic EGFR

Involvement Of Egfr In The Promotion Of Malignant Properties In Multidrug Resistant Breast Cancer Cells